Markus Otto is professor of neurology at the Ulm University Hospital, Department of Neurology in Germany, and head of the outpatient department. He is an internationally renowned expert in the discovery, validation and implementation of biomarkers for neurodegenerative diseases in cerebrospinal fluid (CSF) with over 250 publications. He is involved in several international research consortia for biomarker research and received research funds of over 14.5 million Euro in recent years. Professor Otto is co-founder and member of the speaker board of the Society for CSF analysis and Clinical Neurochemistry. He is also speaker of the German network for frontotemporal lobar degeneration (FTLD) and was chair of the German CSF Society. As the leading clinician, he is responsible for a clinical trial on tau immunization in FTLD patients. His group is well equipped with state-of-the-art mass spectrometry.